These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11928869)

  • 1. Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices.
    Brustmann H
    Pathol Res Pract; 2002; 198(2):85-90. PubMed ID: 11928869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer.
    Kalogeraki A; Karvela-Kalogeraki I; Petraki PE; Zois I; Tamiolakis D; Stathopoulos EN
    Cytopathology; 2011 Dec; 22(6):383-6. PubMed ID: 20738358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
    Brustmann H
    Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.
    McMenamin ME; O'Neill AJ; Gaffney EF
    Mol Pathol; 1997 Oct; 50(5):242-6. PubMed ID: 9497913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
    Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
    Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
    Brustmann H
    Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
    Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
    Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
    Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
    Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
    Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
    Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Architectural patterns of ovarian/pelvic high-grade serous carcinoma.
    Bromley AB; Altman AD; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Han G; Köbel M
    Int J Gynecol Pathol; 2012 Sep; 31(5):397-404. PubMed ID: 22833078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.